Moleculin Reports 2025 Results, Trial Data Near

Moleculin has released its full-year 2025 financial results, confirming that interim data from its pivotal MIRACLE trial is on track for unblinding in mid-2026. Preliminary blinded data from the first 30 patients in the CRc arm of the trial shows a 40% response rate in relapsed/refractory AML, suggesting encouraging early efficacy. This development marks a significant milestone in the company's efforts to advance its novel cancer therapies.